October 29, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools

QIAGEN expands QIAGEN Clinical Insight software to support all major sequencing platforms and assay types

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bioinformatics solutions to deliver expanded Sample to Insight workflows for clinical next-generation sequencing (NGS). QIAGEN introduced QCI Analyze Universal for full end-to-end workflow support of all... Read more

October 29, 2018 Atomic Spectroscopy Clinical Research/Diagn. Life Science Tools Microscopy

QIAGEN expands next-generation sequencing portfolio with oncology and immuno-oncology panels for research using GeneReader NGS System and other platforms 

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QIAGEN’s GeneReader NGS System and other NGS platforms. QIAGEN is introducing the novel NGS workflows for clinical research in... Read more

October 29, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Bio-Rad Receives U.S. FDA Clearance for the IH-Reader 24, Expanding the Company’s Offering for the Blood Typing Market

Date: 10/29/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories. A combination centrifuge and... Read more

October 29, 2018 Clinical Research/Diagn. M&A, Partnerships

MacroGenics and NanoString Enter Translational Research Collaboration to Identify and Develop Biomarkers in Immuno-Oncology

PDF Version Translational Research Initiative Will Use PanCancer IO 360 Panel to Identify Predictive Signatures for MGD013 SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that MacroGenics(NASDAQ:MGNX) and NanoString have entered into a translational research agreement to identify and develop biomarkers for MacroGenics’ MGD013 program.... Read more

October 25, 2018 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System

PDF Version Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today announced the publication of the 10,000 Immunomes Project (10KIP), a seminal human immune reference standard containing mass cytometry immune cell profiles,... Read more

October 25, 2018 Clinical Research/Diagn. Informatics & Software Product Launch

CrownBio Releases MuBase® 2.0. An Open Access Database of Immuno-Oncology Murine Models

October 25, 2018 Updates enhance user experience, provide comprehensive characterization data, and add new models (San Diego, Calif., Oct. 25 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has released MuBase 2.0. MuBase is CrownBio’s proprietary, free-to-access online database featuring... Read more

October 25, 2018 Clinical Research/Diagn. M&A, Partnerships

GE Healthcare and Shirazi Trading host continuous educational workshops for Pakistan’s leading cardiologists and radiologists

Islamabad, Pakistan; October 08, 2018: GE Healthcare (NYSE: GE), in collaboration with Shirazi Trading, held a series of Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Imaging workshops in Rawalpindi, Pakistan. The workshops, led by renowned cardiologist Dr. Saima Mushtaq, GE Healthcare’s Clinical Leaders for CT and MRI, Murat Karakoc and Dr. Ibrahim Elmogy, brought... Read more

October 24, 2018 Clinical Research/Diagn.

Recently released: 2 new Ph. Eur. Reference standards Zoledronic acid monohydrate and Infliximab BRP, as well as 16 replacement batches Back

PRODUCTS AND SERVICES NEWS 24 OCTOBER 2018 STRASBOURG, FRANCE 2 new Ph. Eur. Reference Standards and 16 replacement batches Y0002020 Zoledronic acid monohydrate  and Y0002110 Infliximab BRP Y0000740 Adrenaline impurity mixture, T1410000 Tiabendazole , E2250000 Ethosuximide impurity A, R0800000Rifampicin quinone , Y0000026 Sumatriptan impurity mixture, M0500000 Mepyramine maleate, C1950000Chlortalidone, T1899990 Triamcinolone, B1158000 Bumetanide , Y0000272 Oxaliplatin impurity B, Y0000073 Cetyl palmitate, Y0001341 Oseltamivir impurity H, H0200000 Heparin sodium BRP, B0305000 Beclometasone dipropionate anhydrous, S0150000  Salbutamol sulfate and A0575000 Amiodarone hydrochloride Content of the European Pharmacopoeia catalogue... Read more

October 24, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Agena and DaRui Biotechnology Announce China FDA Clearance of MassARRAY® Technology for Diagnostic Use in China

23 October 2018 San Diego, CA and Guangzhou, China, Wednesdy, October 24, 2018 – Agena Bioscience (Agena) and DaRui Biotechnolog (DaRui) announced today that the MassARRAY® System has formally passed the registration application of Guangdon Food and Drug Administration, becoming the first CFDA approved MALDI-TOF mass spectrometry system to directly detect nucleic acids for in vitro diagnostics in... Read more

October 23, 2018 Clinical Research/Diagn.

BD To Invest $200 Million In Nebraska Operations Creating 300 More Jobs

Brings Total Company Investment in Nebraska to $340 Million in Two Years COLUMBUS, Neb., Oct. 23, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to announce a $200 million investment in its facilities in Nebraska that will create 300 new jobs statewide. Today’s... Read more